Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FAHF-2 in Food Allergy
NCT00602160Phase 2
Key facts
- Status
- Unknown
- Start
- Dec 2007
- Primary completion
- May 2012
- Countries
- 1
- Modality
- Small Molecules
- Drugs
- FAHF-2
- Conditions
- food allergy
01
Overview
Phase 2, randomised, double-blind trial of FAHF-2 in food allergy. Primary endpoint: Safety of FAHF-2 at 1 year. Status: unknown.
02
Design
- Study design
- RandomizedDouble-blind
03
Who it enrols
Patients aged 12-45 with confirmed allergy to peanut, tree nuts, sesame, fish, or shellfish via skin test/IgE and DBPCFC, excluding those with life-threatening anaphylaxis or uncontrolled asthma.
04
Endpoints
Primary
Safety of FAHF-2
Beyond the preview
Go deeper on NCT00602160.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00602160.